Further analysis showed significantly elevated levels of IFN‐γ (4.70 pg mL−1 [IQR, 2.73–10.80] vs. 2.70 pg mL−1 [IQR, 1.70–5.50], p < 0.001) and IL‐17 (12.40 pg mL−1 [IQR, 8.35–27.10] vs. 2.55 pg mL−1 [IQR, 1.38–9.20], p < 0.001) in the peripheral blood of acute exacerbation MG patients compared with those in the stable phase (Figure 3F). The gene discussed is IL17A; the disease is myasthenia gravis.